Similarly, KRAS mutations in tumor cells promote glutamine metabolism by inducing the expression of glutamate oxaloacetate transaminase (GOT), contributing to the maintenance of tumor cell proliferation and survival (53, 54). The gene discussed is KRAS; the disease is neoplasm.